Abstract
BackgroundGene expression profiling of breast cancers identifies distinct molecular subtypes that affect prognosis. The aim of this study was to determine whether features of tumors especially the risks of lymph node (LN) metastases differ among molecular subtypes.MethodsSubtypes were classified by immunohistochemical surrogates as luminal A, luminalHer2−, luminalHer2+, TNBC, and HER-2+. Data were obtained from an established, registered database of patients with invasive breast cancer treated at our hospital between July 2012 and October 2014. A total of 929 tumors were classifiable into molecular subtypes.ResultsThe distribution of subtypes was luminal A (24.2 %), luminalHer2− (27.8 %), luminalHer2+ (9.1 %), TNBC (21.3 %), and HER-2+ (17.5 %). Marked differences in age, tumor size, extent of lymph node involvement, and grade were observed among subtypes. On univariate analysis, the LN positivity varied across subtypes with 33.6 % in luminal A, 40.3 % in luminalHer2−, 37.3 % in luminalHer2+, 37.6 % in TNBC, and 47.4 % in HER-2+ (p = 0.201). There was no significant difference in LN positivity among subtypes. On multivariable analysis, grade and tumor size were independent predictors of LN positivity.ConclusionsPredictors of LN metastases include higher grade and larger tumor size. Even though breast cancer subtype is not a statistically significant predictor of LN positivity, this information may still be useful in selecting the appropriate therapy in clinical practice.
Highlights
Gene expression profiling of breast cancers identifies distinct molecular subtypes that affect prognosis
Gene expression profiling based on 496 genes has identified distinct molecular subtypes of breast cancer that differ in prognosis
Studies have demonstrated that patients with HER-2+ and TNBC tumors have poorer survival compared with patients with luminal A and luminal B tumors and that those with luminal A tumors have a better prognosis than those with luminal B tumors [1, 2]
Summary
Gene expression profiling of breast cancers identifies distinct molecular subtypes that affect prognosis. The aim of this study was to determine whether features of tumors especially the risks of lymph node (LN) metastases differ among molecular subtypes. Gene expression profiling based on 496 genes has identified distinct molecular subtypes of breast cancer that differ in prognosis. Molecular subtype seems to be associated with the risk of local failure for patients treated with breast-conserving therapy and for those treated with mastectomy [3, 4]. Little is known about whether the presenting characteristics especially the axillary lymph node status of breast cancer differ by molecular subtype.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
